Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

The addition of novel anti–LAG-3 antibody relatlimab-rmbw to antiPD-1 antibody nivolumab offers treatment-naïve patients with unresectable or metastatic melanoma an efficacious and tolerable immunotherapy...

Navitoclax plus ruxolitinib produced an improvement in bone marrow fibrosis and a reduction in variant allele frequency in patients with myelofibrosis who progressed on...

Mashup Score:12

OncLive

Dr Braun explains how biomarkers help to stratify treatment decision-making for patients with...

Rahul Banerjee, MD, discusses how to navigate the obstacles in interpreting Kaplan-Meier...

The investigational Wee1 inhibitor ZN-c3 was found to be safe and to produce a disease control rate of 90.9% and an objective response rate...

Mark C. Markowski, MD, PhD, discusses the safety and efficacy of sabizabulin in a phase 1b/2 trial in metastatic castration-resistant prostate...

The FDA has granted a fast track designation to the antibody-drug conjugate CMG901 as a single-agent treatment for patients with unresectable or metastatic gastric...

Ruben Mesa, MD, Jamile M. Shammo, MD, FASCP, FACP, Angela G. Fleischman, MD, PhD, and Stephen T. Oh, MD, PhD discuss the emerging treatment...

William J. Gradishar, MD, discusses the expansion of antibody-drug conjugates across subsets of breast cancer, along with emerging treatment options within each...

In a 16 to 0 vote, with 1 abstention, the FDA’s Oncologic Drugs Advisory Committee voted in support of basing future approvals for PI3K...

  • 1528964022825013248 Profile photo of Madelyn

    In a 16 to 0 vote, with 1 abstention, the FDA’s Oncologic Drugs Advisory Committee voted in support of basing future approvals for PI3K inhibitors on randomized data instead of single-arm clinical trials. @US_FDA #oncology #hematology https://t.co/tRwkgx4Aht - view on twitter